Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients
Overview
- Phase
- Early Phase 1
- Intervention
- Chemotherapy
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma
- Sponsor
- M.D. Anderson Cancer Center
- Enrollment
- 32
- Locations
- 7
- Primary Endpoint
- Proportion of patients who successfully complete 6 cycles of chemotherapy with propranolol hydrochloride
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
This early phase I trial studies giving propranolol hydrochloride with standard chemotherapy in treating patients with ovarian, primary peritoneal, or fallopian tube cancer. Biological therapies, such as propranolol hydrochloride, blocks certain chemicals that affect the heart and this may stimulate the immune system and allow the chemotherapy to kill more tumor cells.
Detailed Description
PRIMARY OBJECTIVES: I. To determine the feasibility of pharmacologic beta-adrenergic blockade in women with stages II-IV epithelial ovarian cancer patients (n=25) either during initial tumor reductive surgery and through the first six cycles of standard intravenous chemotherapy or during neoadjuvant chemotherapy followed by surgery and further chemotherapy (chemo) up to a total of 6 cycles. SECONDARY OBJECTIVES: I. To characterize the biobehavioral states of these patients by using the Functional Assessment of Chronic Illness and Therapy- Ovary (FACT-O), Hospital Anxiety and Depression Survey (HADS) and the Center for Epidemiologic Studies Depression Scale (CESD) and serum levels of angiogenic cytokines at points pre- and post-treatment with beta-blockers. II. To follow patients for progression-free survival (PFS) and overall survival (OS). TRANSLATIONAL OBJECTIVES: I. Determining vascular endothelial growth factor (VEGF), interleukin (IL)-6, IL-8, and other cytokines levels in patients with ovarian cancer who are receiving beta-blockers and comparing these levels pre-treatment and during treatment with response. OUTLINE: Patients receive propranolol hydrochloride orally (PO) twice daily (BID) beginning 48-72 hours before treatment. Patients undergoing surgery resume propranolol hydrochloride post-operatively once oral drugs are tolerated and continue until completion of 6 cycles of chemotherapy. Patients undergoing neoadjuvant chemotherapy continue propranolol hydrochloride PO BID during 3 chemotherapy cycles pre-surgery and 3 cycles post-surgery. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 1 year.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Suspected preoperative diagnosis of invasive epithelial ovarian cancer, primary peritoneal carcinoma, fallopian tube cancer based on imaging and cancer antigen (Ca) 125; histologic epithelial cell types are eligible: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell carcinoma, mixed epithelial carcinoma, or adenocarcinoma not otherwise specified; patients with primarily carcinoma histology but mixed features can be included; the surgically confirmed histologic features must be compatible with primary Mullerian epithelial adenocarcinoma
- •Stages II-IV of the above cancer
- •Patients to be scheduled for a planned tumor debulking
- •Intention for chemotherapy administration at MD Anderson Cancer Center
- •Zubrod performance status 0-2
- •Absolute neutrophil count (ANC) \>= 1500/ml
- •Platelets \> 100,000/mL
- •Creatinine clearance (CrCl) \> 50 mL/min
- •Bilirubin =\< 1.5 x institutional upper limit normal
- •Serum glutamic oxaloacetic transaminase (SGOT) =\< 2.5 x institutional upper limit normal
Exclusion Criteria
- •Patients with non-epithelial ovarian tumors that do not require adjuvant chemotherapy, borderline epithelial ovarian tumor, or recurrent invasive epithelial ovarian, low grade ovarian cancer, primary peritoneal, or fallopian tube cancer treated with surgery only (such as patients with stage IA or IB); patients with a prior diagnosis of a borderline tumor that was surgically resected and who subsequently develop an unrelated new invasive epithelial ovarian, primary peritoneal, or fallopian tube cancer are eligible, provided that they have not received chemotherapy for any tumor; no stromal cancers or germ cell cancers or low malignant potential; patients found post operatively to have ineligible histology will be removed from the study
- •Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded; prior radiation therapy for localized cancer of the breast, head and neck, or skin is permitted provided that it was completed more than 3 years prior to registration, and the patient remains free of recurrent or metastatic disease
- •Patients with a synchronous primary endometrial cancer, or a past history of primary endometrial cancer are excluded unless all of the following conditions are met: stage not greater than stage IA; no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous, clear cell, or other International Federation of Gynecology and Obstetrics (FIGO) grade 3 lesions
- •Patients who have received targeted therapy (including but not limited to vaccines, antibodies, tyrosine kinase inhibitors) or hormonal therapy for management of their primary peritoneal, ovarian, or fallopian tube cancer
- •With the exception of non-melanoma skin cancer and other specific malignancies as noted above, patients with other invasive malignancies who had (or have) any evidence of the other cancer present within the last five years or whose previous cancer treatment contraindicates this protocol therapy are excluded
- •Metastases to the ovaries from other organs except fallopian tube or primary peritoneal carcinoma
- •Use of systemic glucocorticoids such as prednisone or Decadron in the last month
- •Inability to accurately answer questions (e.g. dementia, brain metastases) or speak English or Spanish
- •Cirrhosis of the liver
- •Patients with a Zubrod performance status 3 or 4
Arms & Interventions
Treatment (propranolol hydrochloride)
Patients receive propranolol hydrochloride PO BID beginning 48-72 hours before treatment. Patients undergoing surgery resume propranolol hydrochloride post-operatively once oral drugs are tolerated and continue until completion of 6 cycles of chemotherapy. Patients undergoing neoadjuvant chemotherapy continue propranolol hydrochloride PO BID during 3 chemotherapy cycles pre-surgery and 3 cycles post-surgery. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
Intervention: Chemotherapy
Treatment (propranolol hydrochloride)
Patients receive propranolol hydrochloride PO BID beginning 48-72 hours before treatment. Patients undergoing surgery resume propranolol hydrochloride post-operatively once oral drugs are tolerated and continue until completion of 6 cycles of chemotherapy. Patients undergoing neoadjuvant chemotherapy continue propranolol hydrochloride PO BID during 3 chemotherapy cycles pre-surgery and 3 cycles post-surgery. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
Intervention: Propranolol Hydrochloride
Treatment (propranolol hydrochloride)
Patients receive propranolol hydrochloride PO BID beginning 48-72 hours before treatment. Patients undergoing surgery resume propranolol hydrochloride post-operatively once oral drugs are tolerated and continue until completion of 6 cycles of chemotherapy. Patients undergoing neoadjuvant chemotherapy continue propranolol hydrochloride PO BID during 3 chemotherapy cycles pre-surgery and 3 cycles post-surgery. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
Intervention: Quality-of-Life Assessment
Treatment (propranolol hydrochloride)
Patients receive propranolol hydrochloride PO BID beginning 48-72 hours before treatment. Patients undergoing surgery resume propranolol hydrochloride post-operatively once oral drugs are tolerated and continue until completion of 6 cycles of chemotherapy. Patients undergoing neoadjuvant chemotherapy continue propranolol hydrochloride PO BID during 3 chemotherapy cycles pre-surgery and 3 cycles post-surgery. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
Intervention: Therapeutic Conventional Surgery
Outcomes
Primary Outcomes
Proportion of patients who successfully complete 6 cycles of chemotherapy with propranolol hydrochloride
Time Frame: Up to 6 months
The success rate will be estimated with a 90% credible interval.
Secondary Outcomes
- Changes in quality of life as measured by the Functional Assessment of Chronic Illness and Therapy- Ovary (FACT-O)(Baseline to up to 6 months)
- Overall survival (OS)(Up to 1 year)
- Progression-free survival (PFS)(Up to 1 year)
- Incidence of adverse events(Up to 1 year after completion of study treatment)
- Changes in mood state as measured by Center for Epidemiologic Studies Depression Scale (CES-D(Baseline to up to 6 months)
- Changes in mood state as measured by the Hospital Anxiety and Depression Survey (HADS)(Baseline to up to 6 months)